Esperion Therapeutics, Inc. (ESPR)
USD 1.0
(-2.05%)
USD 1.0
(-2.05%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 271.89 Million USD | 0.2% |
| 2022 | 228 Million USD | -21.64% |
| 2021 | 290.96 Million USD | -16.04% |
| 2020 | 346.55 Million USD | 43.52% |
| 2019 | 241.46 Million USD | 18.03% |
| 2018 | 204.58 Million USD | 21.07% |
| 2017 | 168.98 Million USD | 121.91% |
| 2016 | 76.15 Million USD | 52.18% |
| 2015 | 50.04 Million USD | 38.14% |
| 2014 | 36.22 Million USD | 59.17% |
| 2013 | 22.75 Million USD | 123.04% |
| 2012 | 10.2 Million USD | 0.39% |
| 2011 | 10.16 Million USD | 0.0% |
| 2002 | 29.23 Million USD | -0.32% |
| 2001 | 29.33 Million USD | 9.49% |
| 2000 | 26.78 Million USD | 129.25% |
| 1999 | 11.68 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 55.63 Million USD | -15.02% |
| 2024 Q1 | 65.46 Million USD | 3.65% |
| 2023 FY | 228.46 Million USD | 0.2% |
| 2023 Q1 | 61.28 Million USD | 7.19% |
| 2023 Q4 | 63.15 Million USD | 2.69% |
| 2023 Q2 | 62.84 Million USD | 2.55% |
| 2023 Q3 | 61.5 Million USD | -2.14% |
| 2022 FY | 228 Million USD | -21.64% |
| 2022 Q4 | 57.17 Million USD | 5.68% |
| 2022 Q3 | 54.09 Million USD | -12.8% |
| 2022 Q2 | 62.04 Million USD | 13.42% |
| 2022 Q1 | 54.7 Million USD | -17.06% |
| 2021 Q4 | 65.95 Million USD | 2.1% |
| 2021 Q3 | 64.59 Million USD | -9.52% |
| 2021 Q2 | 71.39 Million USD | -19.8% |
| 2021 Q1 | 89.01 Million USD | -14.01% |
| 2021 FY | 290.96 Million USD | -16.04% |
| 2020 Q1 | 76.25 Million USD | 27.21% |
| 2020 FY | 346.55 Million USD | 43.52% |
| 2020 Q3 | 84.1 Million USD | 1.74% |
| 2020 Q4 | 103.51 Million USD | 23.08% |
| 2020 Q2 | 82.66 Million USD | 8.41% |
| 2019 Q4 | 59.94 Million USD | -10.19% |
| 2019 Q1 | 58.49 Million USD | -3.56% |
| 2019 Q2 | 56.28 Million USD | -3.78% |
| 2019 Q3 | 66.74 Million USD | 18.6% |
| 2019 FY | 241.46 Million USD | 18.03% |
| 2018 Q2 | 46.48 Million USD | -0.88% |
| 2018 FY | 204.58 Million USD | 21.07% |
| 2018 Q1 | 46.89 Million USD | 21.19% |
| 2018 Q4 | 60.64 Million USD | 19.95% |
| 2018 Q3 | 50.56 Million USD | 8.78% |
| 2017 Q1 | 40.88 Million USD | 39.62% |
| 2017 FY | 168.98 Million USD | 121.91% |
| 2017 Q4 | 38.69 Million USD | -15.39% |
| 2017 Q3 | 45.73 Million USD | 4.76% |
| 2017 Q2 | 43.66 Million USD | 6.78% |
| 2016 Q2 | 14.33 Million USD | -3.31% |
| 2016 FY | 76.15 Million USD | 52.18% |
| 2016 Q4 | 29.28 Million USD | 65.34% |
| 2016 Q3 | 17.71 Million USD | 23.59% |
| 2016 Q1 | 14.82 Million USD | 12.0% |
| 2015 Q3 | 12.91 Million USD | 3.67% |
| 2015 FY | 50.04 Million USD | 38.14% |
| 2015 Q2 | 12.46 Million USD | 9.08% |
| 2015 Q4 | 13.23 Million USD | 2.44% |
| 2015 Q1 | 11.42 Million USD | 21.8% |
| 2014 Q4 | 9.38 Million USD | -3.3% |
| 2014 Q1 | 7.89 Million USD | -18.96% |
| 2014 Q3 | 9.7 Million USD | 4.82% |
| 2014 FY | 36.22 Million USD | 59.17% |
| 2014 Q2 | 9.25 Million USD | 17.29% |
| 2013 FY | 22.75 Million USD | 123.04% |
| 2013 Q1 | 3.34 Million USD | 54.81% |
| 2013 Q2 | 4.27 Million USD | 27.75% |
| 2013 Q3 | 5.4 Million USD | 26.57% |
| 2013 Q4 | 9.73 Million USD | 80.07% |
| 2012 Q2 | 2.86 Million USD | 30.8% |
| 2012 Q4 | 2.16 Million USD | -27.76% |
| 2012 Q3 | 2.99 Million USD | 4.41% |
| 2012 Q1 | 2.18 Million USD | 0.0% |
| 2012 FY | 10.2 Million USD | 0.39% |
| 2011 FY | 10.16 Million USD | 0.0% |
| 2003 Q3 | 6.45 Million USD | -20.8% |
| 2003 Q2 | 8.15 Million USD | 10.1% |
| 2003 Q1 | 7.4 Million USD | 14.5% |
| 2002 Q2 | 7.67 Million USD | -0.45% |
| 2002 FY | 29.23 Million USD | -0.32% |
| 2002 Q3 | 7.38 Million USD | -3.82% |
| 2002 Q4 | 6.46 Million USD | -12.41% |
| 2002 Q1 | 7.71 Million USD | 19.44% |
| 2001 Q2 | 8.19 Million USD | -1.81% |
| 2001 FY | 29.33 Million USD | 9.49% |
| 2001 Q4 | 6.45 Million USD | -11.06% |
| 2001 Q3 | 7.25 Million USD | -11.43% |
| 2001 Q1 | 8.34 Million USD | 33.72% |
| 2000 Q2 | 7.25 Million USD | 32.48% |
| 2000 Q1 | 5.47 Million USD | 0.0% |
| 2000 Q3 | 7.82 Million USD | 7.83% |
| 2000 Q4 | 6.24 Million USD | -20.18% |
| 2000 FY | 26.78 Million USD | 129.25% |
| 1999 FY | 11.68 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -70.781% |
| Embecta Corp. | 528.4 Million USD | 48.543% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -38.735% |
| Dynavax Technologies Corporation | 219.14 Million USD | -24.072% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 16.692% |
| PainReform Ltd. | 9.58 Million USD | -2736.989% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -506.182% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1971.68% |
| SCYNEXIS, Inc. | 51.84 Million USD | -424.412% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -8758.923% |
| Cosmos Health Inc. | 26.18 Million USD | -938.536% |
| Journey Medical Corporation | 54.59 Million USD | -398.035% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -1971.68% |
| Safety Shot Inc | 12.1 Million USD | -2145.284% |
| Alpha Teknova, Inc. | 45.85 Million USD | -492.898% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 53.916% |
| Bright Green Corporation | 8.25 Million USD | -3194.574% |
| Procaps Group, S.A. | 199.47 Million USD | -36.305% |
| Theratechnologies Inc. | 72.75 Million USD | -273.711% |
| Harrow Health, Inc. | 89.97 Million USD | -202.198% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -2778.435% |
| Biofrontera Inc. | 39.95 Million USD | -580.44% |
| DURECT Corporation | 43.71 Million USD | -521.976% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 48.603% |
| Cronos Group Inc. | 96.7 Million USD | -181.15% |
| OptiNose, Inc. | 85.1 Million USD | -219.495% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -17.134% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -594.447% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 2943.813% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 13.446% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -2694.18% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -531.723% |
| Radius Health, Inc. | 265.92 Million USD | -2.244% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -1864.303% |
| ProPhase Labs, Inc. | 37.85 Million USD | -618.316% |
| Phibro Animal Health Corporation | 260.29 Million USD | -4.456% |
| Procaps Group S.A. | 187.24 Million USD | -45.209% |
| Alvotech | 285.43 Million USD | 4.744% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -2667.399% |
| Viatris Inc. | 5.96 Billion USD | 95.443% |
| Rockwell Medical, Inc. | 15.37 Million USD | -1668.551% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -354.373% |
| SIGA Technologies, Inc. | 22.04 Million USD | -1133.483% |
| Tilray Brands, Inc. | 251.35 Million USD | -8.172% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -454.462% |
| Shineco, Inc. | 17.94 Million USD | -1414.912% |
| PetIQ, Inc. | 192.72 Million USD | -41.08% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -6712.518% |
| Incannex Healthcare Limited | 30.05 Million USD | -804.725% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 82.969% |
| Alimera Sciences, Inc. | 62.64 Million USD | -334.056% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -35558.997% |
| Assertio Holdings, Inc. | 368.58 Million USD | 26.232% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -4519.722% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1426.779% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -1184.411% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1192.157% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -64.82% |
| Hempacco Co., Inc. | 7.59 Million USD | -3479.264% |
| Talphera, Inc. | 11.99 Million USD | -2166.942% |
| Alvotech | 285.43 Million USD | 4.744% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -93.227% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 21.167% |
| Currenc Group, Inc. | 24 Million USD | -1032.806% |
| Kamada Ltd. | 45.42 Million USD | -498.549% |
| Indivior PLC | 911 Million USD | 70.154% |
| Evoke Pharma, Inc. | 12.4 Million USD | -2091.014% |
| Flora Growth Corp. | 10.57 Million USD | -2470.158% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1192.157% |
| Evolus, Inc. | 189.75 Million USD | -43.285% |
| HUTCHMED (China) Limited | 436.23 Million USD | 37.671% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -76.403% |
| Akanda Corp. | 3.48 Million USD | -7705.264% |